Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,800 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 June 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 229 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 16 results:
Author Title Type [ Year(Asc)]
Filters: Author is Strongman, H.  [Clear All Filters]
2021
K. E. Mansfield, Mathur, R., Tazare, J., Henderson, A. D., Mulick, A. R., Carreira, H., Matthews, A. A., Bidulka, P., Gayle, A., Forbes, H., Cook, S., Wong, A. Y. S., Strongman, H., Wing, K., Warren-Gash, C., Cadogan, S. L., Smeeth, L., Hayes, J. F., Quint, J. K., McKee, M., and Langan, S. M., “Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study”, Lancet Digit Health, 2021.
J. L. Walker, Grint, D. J., Strongman, H., Eggo, R. M., Peppa, M., Minassian, C., Mansfield, K. E., Rentsch, C. T., Douglas, I. J., Mathur, R., Wong, A. Y. S., Quint, J. K., Andrews, N., Bernal, J. L., Scott, J. A., Ramsay, M., Smeeth, L., and McDonald, H. I., “UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records”, BMC Public Health, vol. 21, p. 484, 2021.
2020
H. Carreira, Strongman, H., Peppa, M., McDonald, H., dos-Santos-Silva, I., Stanway, S., Smeeth, L., and Bhaskaran, K., “Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: A matched cohort study using linked English electronic health records data”, EClinicalMedicine, 2020.
H. Strongman, Williams, R., and Bhaskaran, K., “What are the implications of using individual and combined sources of routinely collected data to identify and characterise incident site-specific cancers? a concordance and validation study using linked English electronic health records data”, BMJ Open, vol. 10, p. e037719, 2020.
2019
H. Strongman, Brown, A., Smeeth, L., and Bhaskaran, K., “Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals”, Br J Cancer, 2019.
H. Carreira, Williams, R., Strongman, H., and Bhaskaran, K., “Identification of mental health and quality of life outcomes in primary care databases in the UK: a systematic review”, BMJ Open, vol. 9, p. e029227, 2019.
H. Strongman, Williams, R., Meeraus, W., Murray-Thomas, T., Campbell, J., Carty, L., Dedman, D., Gallagher, A., Oyinlola, J., Kousoulis, A., and Valentine, J., “Limitations for health research with restricted data collection from UK primary care”, Pharmacoepidemiol Drug Saf, 2019.
H. Strongman, Gadd, S., Matthews, A., Mansfield, K. E., Stanway, S., Lyon, A. R., dos-Santos-Silva, I., Smeeth, L., and Bhaskaran, K., “Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases”, Lancet, 2019.
2018
S. Padmanabhan, Carty, L., Cameron, E., Ghosh, R. E., Williams, R., and Strongman, H., “Approach to record linkage of primary care data from Clinical Practice Research Datalink to other health-related patient data: overview and implications”, Eur J Epidemiol, 2018.
H. Strongman, Kausar, I., and Maher, T. M., “Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK”, Adv Ther, vol. 35, pp. 724-736, 2018.
H. Strongman, Christopher, S., Majak, M., Williams, R., Bahmanyar, S., Linder, M., Heintjes, E. M., Bennett, D., Korhonen, P., and Hoti, F., “Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study”, BMJ Open Diabetes Res Care, vol. 6, p. e000481, 2018.
K. Chidwick, Strongman, H., Matthews, A., Stanway, S., Lyon, A. R., Smeeth, L., and Bhaskaran, K., “Statin use in cancer survivors versus the general population: cohort study using primary care data from the UK clinical practice research datalink”, BMC Cancer, vol. 18, p. 1018, 2018.
2017
H. Strongman, Korhonen, P., Williams, R., Bahmanyar, S., Hoti, F., Christopher, S., Majak, M., Kool-Houweling, L., Linder, M., Dolin, P., and Heintjes, E. M., “Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study”, BMJ Open Diabetes Res Care, vol. 5, p. e000364, 2017.
2016
P. Korhonen, Heintjes, E. M., Williams, R., Hoti, F., Christopher, S., Majak, M., Kool-Houweling, L., Strongman, H., Linder, M., Dolin, P., and Bahmanyar, S., “Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries”, Bmj, vol. 354, p. i3903, 2016.
2015
H. Strongman, D'Oca, K., Langerman, H., and Das, R., “Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study”, Diabetes Obes Metab, vol. 17, pp. 573-80, 2015.
2014
R. Das, Langerman, H., D'Oca, K., and Strongman, H., “An Observational Cohort Study of Diabetes-Associated Secondary Health Care Utilisation in Patients With Type 2 Diabetes Prescribed Dual Combination Therapy With Oral Anti-Hyperglycaemic Agents in the UK”, Value Health, vol. 17, p. A360, 2014.
[Page last reviewed 4 June 2021]